Cargando…

Effects of adalimumab and secukinumab on comorbidities associated with metabolism in patients with plaque psoriasis

Detalles Bibliográficos
Autores principales:	Zhang, Si, Cai, Lin, Zhang, Heng, Zhao, Zheng, Liu, Xiaoyang, Zhao, Yan, Zhang, Jianzhong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9771182/ https://www.ncbi.nlm.nih.gov/pubmed/35838381 http://dx.doi.org/10.1097/CM9.0000000000002143

Ejemplares similares

Effects of secukinumab and adalimumab on serum uric acid level in patients with plaque psoriasis
por: Zhao, Zheng, et al.
Publicado: (2022)

Effectiveness and safety of secukinumab in Chinese patients with plaque psoriasis in a clinical practice setting: a pilot study
por: Zhu, Si-Man, et al.
Publicado: (2020)

Secukinumab for Recalcitrant Chronic Plaque Psoriasis in a 9 Year Old Child
por: Shruthi, R, et al.
Publicado: (2021)

Comparative efficacy of secukinumab against adalimumab and infliximab in patients with moderate-to-severe plaque psoriasis
por: Pan, Ran, et al.
Publicado: (2022)

Efficacy and safety of secukinumab in Chinese patients with moderate-to-severe plaque psoriasis: a real-life cohort study
por: Zhao, Yan, et al.
Publicado: (2021)

Successful treatment of adalimumab-resistant palmoplantar pustulosis with secukinumab: a case report
por: Li, Qing-Yang, et al.
Publicado: (2020)

Effects of secukinumab on metabolic and liver parameters in plaque psoriasis patients
por: Gerdes, S., et al.
Publicado: (2019)

Successful treatment of generalized pustular psoriasis with secukinumab: a report of two cases
por: Sun, Zhi-Lin, et al.
Publicado: (2020)

Secukinumab in the Treatment of Plaque Psoriasis in Patients with Malignancy
por: Gambardella, Alessio
Publicado: (2019)

Secukinumab: Rapid Efficacy in Psoriasis After Primary Failure With Ustekinumab and Adalimumab
por: Okita, Aline Lissa, et al.
Publicado: (2020)

Resolution of post-adalimumab vitiligo with secukinumab in a patient with psoriasis vulgaris
por: Palazzo, Giovanni
Publicado: (2020)

Long-Term Psoriasis Control with Guselkumab, Adalimumab, Secukinumab, or Ixekizumab in the USA
por: Fitzgerald, Timothy, et al.
Publicado: (2023)

Successful secukinumab treatment in focal segmental glomerulosclerosis associated with plaque psoriasis
por: Cao, Zhiqiang, et al.
Publicado: (2022)

Efficacy, Safety, and Pharmacoeconomic Analysis of Adalimumab and Secukinumab for Moderate-to-Severe Plaque Psoriasis: A Single-Center, Real-World Study
por: Li, Gaojie, et al.
Publicado: (2022)

Position Statement on Secukinumab in the Management of Plaque Psoriasis: The Malaysian Perspective
por: Johar, Asmah, et al.
Publicado: (2019)

Addition of Cyclosporine to Adalimumab Improved Psoriasis And Adalimumab-Induced Injection Site Reaction
por: Nakamizo, Satoshi, et al.
Publicado: (2014)

Assessment of serum biomarkers in patients with plaque psoriasis on secukinumab
por: Morita, Akimichi, et al.
Publicado: (2020)

Efficacy of Secukinumab for Plaque Psoriasis in a Patient on Hemodialysis
por: Ikuma, Daiuske, et al.
Publicado: (2019)

Real-world investigation of the efficacy and safety of secukinumab for psoriasis treatment in a Chinese population
por: Zeng, Jing-Xin, et al.
Publicado: (2021)

Efficacy and Safety of Secukinumab in Patients with Plaque Psoriasis and Latent Tuberculosis
por: Ribero, Simone, et al.
Publicado: (2019)

Secukinumab: A Review in Moderate to Severe Pediatric Plaque Psoriasis
por: Blair, Hannah A.
Publicado: (2021)

Alopecia Areata After Initiation of Secukinumab Therapy for Plaque Psoriasis
por: Choi, Esther, et al.
Publicado: (2023)

Treatment with secukinumab for plaque psoriasis in patients with infectious comorbidities and latent tuberculosis: A multi‐case report analysis
por: Fiorella, Carmen
Publicado: (2022)

Response to the Letter to the Editor: Long-Term Psoriasis Control with Guselkumab, Adalimumab, Secukinumab, or Ixekizumab in the USA
por: Fitzgerald, Timothy, et al.
Publicado: (2023)

Efficacy and Safety of Secukinumab in Chronic Plaque Psoriasis and Psoriatic Arthritis Therapy
por: Gisondi, Paolo, et al.
Publicado: (2014)

Treatment challenges in the management of moderate-to-severe plaque psoriasis – role of secukinumab
por: Malakouti, Mona, et al.
Publicado: (2016)

Widespread Superficial Dermatophytosis in Patient on Secukinumab for Treatment of Chronic Plaque Psoriasis
por: Neema, Shekhar, et al.
Publicado: (2019)

Correction to: Secukinumab: A Review in Moderate to Severe Pediatric Plaque Psoriasis
por: Blair, Hannah A.
Publicado: (2021)

Visual Loss Induced by Adalimumab Used for Plaque Psoriasis
por: Saffra, Norman, et al.
Publicado: (2017)

Transcriptomic Profiling of Plaque Psoriasis and Cutaneous T-Cell Subsets during Treatment with Secukinumab
por: Liu, Jared, et al.
Publicado: (2021)

Successful secukinumab therapy in plaque psoriasis is associated with altered gut microbiota and related functional changes
por: Du, Xueshan, et al.
Publicado: (2023)

Treatment satisfaction, safety and effectiveness of adding methotrexate to adalimumab in patients with psoriasis responding suboptimally to adalimumab in a real‐world setting
por: Papp, K.A., et al.
Publicado: (2022)

Transition from secukinumab to adalimumab in COVID‐19‐induced psoriasis flare‐up treatment: A case report
por: Chen, Yuting, et al.
Publicado: (2023)

Efficacy and safety of ixekizumab in Chinese patients with plaque psoriasis
por: Huang, He, et al.
Publicado: (2023)

Dyshidrotic eczema in two patients on secukinumab for plaque psoriasis: A case report
por: Bose, Reetesh, et al.
Publicado: (2020)

Drug Survival Outcomes Associated with the Real-World Use of Ixekizumab, Secukinumab, Guselkumab, and Adalimumab for the Treatment of Plaque Psoriasis in China: A 52-Week Single-Center Retrospective Study
por: Li, Ying, et al.
Publicado: (2022)

Chronic inflammatory demyelinating polyneuropathy and psoriasis comorbidity with significantly alleviated in symptoms after secukinumab: case report
por: Jin, Yan, et al.
Publicado: (2022)

Cost effectiveness of ixekizumab versus secukinumab in the treatment of moderate-to-severe plaque psoriasis in Spain
por: Johansson, Erin, et al.
Publicado: (2018)

Burden of Moderate-to-Severe Plaque Psoriasis and New Therapeutic Approaches (Secukinumab): An Italian Perspective
por: Mantovani, Lorenzo, et al.
Publicado: (2016)

Real-world clinical experience of secukinumab in Chinese patients with psoriasis in real-world practice: a 36-week single-center study of 24 patients
por: Zhang, Jing, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_rr9seikg8381oisd8ncqgsfttu